拉帕替尼联合卡培他滨对比曲妥珠单抗耐药的乳腺癌患者继续使用曲妥珠单抗：一项中国人群的回顾性研究。
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
机构信息
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
The First Clinical College of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
出版信息
BMC Cancer. 2020 Mar 29;20(1):255. doi: 10.1186/s12885-020-6639-4.
BACKGROUND
The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown.
METHODS
We retrospectively analyzed data from breast cancer patients who began treatment with regimens of lapatinib plus capecitabine (LC or LX) or trastuzumab beyond progression (TBP) at eight hospitals between May 2010 and October 2017.
RESULTS
Among 554 patients who had developed resistance to trastuzumab, the median PFS (progression free survival) was 6.77 months in the LX group compared with 5.6 months in the TBP group (hazard ratio 0.804; 95% CI, 0.67 to 0.96; P = 0.019). The central nervous system progression rate during treatment was 5.9% in the LX group and 12.5% in the TBP group (P = 0.018).
CONCLUSION
The combination of lapatinib and capecitabine showed a prolonged PFS relative to TBP in patients who had progressed on trastuzumab.
背景
曲妥珠单抗耐药的人表皮生长因子受体 2（HER2）阳性转移性乳腺癌患者中，拉帕替尼联合卡培他滨（LC 或 LX）与曲妥珠单抗联合化疗的疗效和安全性尚不清楚。
方法
我们回顾性分析了 2010 年 5 月至 2017 年 10 月期间，8 家医院中开始接受拉帕替尼联合卡培他滨（LC 或 LX）或曲妥珠单抗治疗方案的转移性乳腺癌患者的数据。
结果
在 554 例曲妥珠单抗耐药的患者中，LX 组的中位无进展生存期（PFS）为 6.77 个月，而 TBP 组为 5.6 个月（风险比 0.804；95%置信区间，0.67 至 0.96；P=0.019）。LX 组治疗期间中枢神经系统进展率为 5.9%，TBP 组为 12.5%（P=0.018）。
结论
与 TBP 相比，在曲妥珠单抗耐药的患者中，拉帕替尼联合卡培他滨显示出更长的 PFS。
Zotero 插件